Whether dominantly inherited variants of Alzheimer disease (AD) and 'sporadic' forms exhibit similar pathophysiological and biomarker signatures remains unresolved. A landmark study has proposed a biomarker progression model of dominantly inherited AD, but a complex systems biology and physiology approach is required to translate these findings to sporadic disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice
Nature Communications Open Access 01 June 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
We are sorry, but there is no personal subscription option available for your country.
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795–804 (2012).
Zetzsche, T., Rujescu, D., Hardy, J. & Hampel, H. Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev. Mol. Diagn. 10, 667–690 (2010).
Hampel, H. Lista, S. & Khachaturian, Z. S. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 8, 312–336 (2012).
Bertram, L. & Hampel, H. The role of genetics for biomarker development in neurodegeneration. Prog. Neurobiol. 95, 501–504 (2011).
Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119–128 (2010).
Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144 (2010).
Faltraco, F., Lista, S., Garaci, F. G. & Hampel, H. Epigenetic mechanisms in Alzheimer's disease: state-of-the-art. Eur. J. Neurodegener. Dis. 1, 1–19 (2012).
Wadman, M. US government sets out Alzheimer's plan. Nature 485, 426–427 (2012).
Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560–574 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H. Hampel has received lecture honoraria and/or research grants and/or travel funding and/or participated in scientific advisory boards of the following pharmaceutical companies that are involved in the manufacture and marketing of diagnostics and/or drugs or medicinal products for Alzheimer disease: Astra-Zeneca, Avid, Bayer, BMS, Boehringer-Ingelheim, Eisai, Elan, Eli Lilly, GE Healthcare, Genentech, GlaxoSmithKline Bio, Janssen-Cilag, Merz Pharmaceuticals, Novartis, Pfizer, Sanofi-Aventis, Schwabe, Roche, and Wyeth. S. Lista declares no competing interests.
Rights and permissions
About this article
Cite this article
Hampel, H., Lista, S. From inherited to sporadic AD—crossing the biomarker bridge. Nat Rev Neurol 8, 598–600 (2012). https://doi.org/10.1038/nrneurol.2012.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.202
